Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
November is Lung Cancer Awareness Month.
Although the improvement in survival with immunotherapy was modest, it is noteworthy because SCLC has been such a recalcitrant disease.
Here’s a list of the approved drugs to treat lung cancer. Click on any of the medications for more info on dosing, side effects and d...
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
A Phase II trial reached its primary endpoint of overall response in just over a third of participants.
Progression-free and overall survival improved in patients treated with Tecentriq plus chemotherapy.
Because so few people diagnosed with SCLC survive for even a year despite treatment, an advance in survival rate is quite significant.
Responses were durable for at least six months in 77% of responders.
First new treatment in two decades for uncommon type of lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.